Drugs / Rociletinib
Rociletinib
also known as
AVL-301 · CNX-419 · CO-1686 · CS-1631 · ROCILETINIB (CO-1686) · ROCILETINIB HYDROBROMIDE
Small molecule targets EGFR via inhibition
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT02630186 | Feb 2016 → Sep 2017 | non-small cell lung carcinoma | Clovis Oncology, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT02580708 | Sep 2015 → May 2016 | non-small cell lung carcinoma | Clovis Oncology, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT01526928 | Mar 2012 → Jul 2018 | non-small cell lung carcinoma | Clovis Oncology, Inc. | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02705339 | May 2016 → Nov 2019 | non-small cell lung carcinoma | Washington University School of Medicine | Withdrawn | No outcome recorded |
| Phase 2 | NCT02147990 | Jun 2014 → Jul 2019 | non-small cell lung carcinoma | Clovis Oncology, Inc. | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02186301 | Nov 2014 → Jun 2017 | non-small cell lung carcinoma | Clovis Oncology, Inc. | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02322281 | Feb 2015 → Mar 2018 | non-small cell lung carcinoma | Clovis Oncology, Inc. | Terminated | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT02547675 | — | non-small cell lung carcinoma | Clovis Oncology, Inc. | No longer available | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rociletinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02322281 ↗ |
| Known as | AVL-301 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545308 ↗ |
| Known as | CNX-419 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545308 ↗ |
| Known as | CO-1686 | “Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC” NCT02186301 ↗ |
| Known as | CS-1631 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545308 ↗ |
| Known as | ROCILETINIB (CO-1686) | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545308 ↗ |
| Known as | ROCILETINIB HYDROBROMIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545308 ↗ |
| Action | Inhibit | “Rociletinib (CO-1686) is an EGFR inhibitor active in preclinical models of EGFR-mutated NSCLC with or without T790M.” PMID 25923550 ↗ Apr 20151“Epidermal growth factor receptor erbB1 inhibitor” CHEMBL3545308 ↗ |
| Modality | Small molecule | “Rociletinib is a novel, potent, small molecule irreversible tyrosine kinase inhibitor (TKI)” NCT01526928 ↗ |
| Route | Oral | “oral rociletinib administered daily” NCT01526928 ↗ |
| Target | EGFR | “Epidermal growth factor receptor erbB1 inhibitor” CHEMBL3545308 ↗ |